Is Jardiance a GLP-1 Medication?
FAQ-000057
Direct Answer
No, Jardiance is not a GLP-1 medication. Its active ingredient, empagliflozin, belongs to a completely different drug class called SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors). Jardiance works by blocking glucose reabsorption in the kidney, causing excess glucose to be excreted in urine, an entirely different mechanism from GLP-1 medications, which work by activating GLP-1 receptors to slow digestion and suppress appetite.
Why the Confusion Is Understandable
Jardiance and GLP-1 medications like Ozempic are often prescribed to the same patient population, people with type 2 diabetes, and both classes have real, established cardiovascular benefits, which can make them blend together in casual conversation. But they are structurally, mechanically, and pharmacologically unrelated. Jardiance is not a peptide or a receptor agonist at all, it's a small-molecule oral tablet that acts entirely within the kidney.
What Jardiance Is Actually Approved For
As of 2026, Jardiance carries FDA approval for blood sugar control in type 2 diabetes, reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, treating heart failure across the full range of ejection fraction, and reducing the risk of kidney disease progression in adults with chronic kidney disease, several of these approvals apply regardless of diabetes status.
Can Jardiance and a GLP-1 Be Taken Together?
Yes, and this is genuinely common in clinical practice. Because the two drug classes work through entirely different mechanisms, they're often prescribed together for patients with type 2 diabetes and cardiovascular or kidney risk factors, without a significant direct interaction between them. This combined use is likely part of why the two get mentally grouped together, even though they aren't the same type of medication.
Bottom Line
If your provider has you on both Jardiance and a GLP-1 medication, that's a legitimate, common combination targeting different aspects of cardiometabolic health, not redundant treatment. But if you're specifically researching GLP-1 medications, Jardiance itself isn't one, and won't be covered as a GLP-1 medication anywhere in this library.
References
- Guideline Central: Boehringer Ingelheim Jardiance (Empagliflozin) Monograph (May 2026)
- Eli Lilly and Company: FDA Approves Jardiance for Chronic Kidney Disease
- StatPearls: Sodium-Glucose Transport 2 (SGLT2) Inhibitors
Related Resources
Related Articles
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
is-jardiance-a-glp-1